Baricitinib restrains the immune dysregulation in patients with severe COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2020.06.26.20135319: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: The study was designed as an observational longitudinal trial and approved by the local ethical committee (Prot. n° 17963, P.I. Vincenzo Bronte); informed consent was obtained from all the participants to the study.
Consent: The study was designed as an observational longitudinal trial and approved by the local ethical committee (Prot. n° 17963, P.I. Vincenzo Bronte); informed consent was obtained from all the participants to the study.Randomization These patients were not considered for the randomized, multi-center clinical trial that will start recruiting. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: …
SciScore for 10.1101/2020.06.26.20135319: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: The study was designed as an observational longitudinal trial and approved by the local ethical committee (Prot. n° 17963, P.I. Vincenzo Bronte); informed consent was obtained from all the participants to the study.
Consent: The study was designed as an observational longitudinal trial and approved by the local ethical committee (Prot. n° 17963, P.I. Vincenzo Bronte); informed consent was obtained from all the participants to the study.Randomization These patients were not considered for the randomized, multi-center clinical trial that will start recruiting. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Statistical significance was set at p-value <0.05, and clinical analyses were performed using statistical software STATA® version 16.0 (StataCorp, College Station, TX, USA). StataCorpsuggested: (Stata, RRID:SCR_012763)For statistical laboratory analyses we performed paired comparisons by Student’s t-test and one-way Anova test for repeated measures, using Graph Pad Prism (San Diego, California, version 8.4.2). Graph Pad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04438629 Recruiting Evaluation of Immune Response in COVID-19 Patients Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-